[The comparison of the humoral response among the patients with liver cirrhosis and steatosis of the liver after HBV vaccination].
The goal of the study was the assessment of the effectiveness of the hepatitis B vaccine among patients with liver diseases. Only those patients without serological markers for HBV infection (HBsAg-, anti-HBcT-, anti-HBs-) were selected. Twenty nine patients were vaccinated. The recombinant vaccine (Engerix-B SKB 20 microg) was used according to a 0, 1, 2 month regime. Serum samples for seroconversion rates and concentration of antiHBs were taken at month 1,2 and 3 after the first injection. The vaccines were divided into two groups. Group 1-16 patients with liver steatosis. Group 2-13 patients suffering from liver cirrhosis. The seroconversion rates and the concentrations of anti-HBs were taken at month 1,2 and 3 after the first injection. Good response to the HBV vaccine was observed in the patients with liver steatosis. 93, 7% of serocoversion to anty HB-s was observed after vaccination. The GMT of anti- HBs was 97,37 IU/l. Patients suffering from liver cirrhosis responded much less favorably to the hepatitis B vaccine than patients with liver steatosis. Seroconversion rate after third dose was 38,5%only, and GMT of anti-HBs was 18,48 IU/l.


CONCLUSIONS
Patients suffering from the liver cirrhosis react much less favorably to the hepatitis B vaccine than patients with the liver steatosis.
Koślińska-Berkan
Ewa
E
Klinika Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Lodzi.
Kuydowicz
Jan
J
D000328:Adult; D000368:Aged; D005234:Fatty Liver / Q000276:immunology*; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006801:Humans; D008103:Liver Cirrhosis / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014614:Vaccines, Synthetic / Q000008:administration & dosage
C075654:Engerix-B; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic